|
DNLI | Denali Therapeutics Inc. |
|
|
DNLI | Denali Therapeutics Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.56 |
| Leverage | 11.93% |
| Market Cap | $ 1.8B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -477.8m |
| Margin | 0.00% |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.